The World Health Organization (WHO) has just released updated consolidated guidelines on the treatment of drug-resistant TB (DR-TB) featuring major improvements in treatment options for people with multidrug-resistant or rifampicin-resistant tuberculosis (MDR/RR-TB). The guidelines include a new recommendation on the use of a novel all-oral 6-month regimen composed of bedaquiline, pretomanid, linezolid and moxifloxacin (BPaLM) in people suffering from MDR/RR-TB or MDR/RR-TB with additional resistance to fluoroquinolones (pre-XDR-TB). The newly recommended BPaLM regimen offers better outcomes, remarkably shortens the duration of treatment, and thus significantly improves quality of life for people with MDR/RR-TB. Read the updated guidelines here.
top of page
bottom of page